Trial reportSleep2012
A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
Trial report in Sleep, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07577661 (Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea), which is not on this map. Cited by 60 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea: A Randomized-Controlled Trial.
Who cites it
60 citing papers in PubMed, 5 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Guideline for the Management of Obesity in Adult Patients With Obstructive Sleep Apnea.Clinical and experimental otorhinolaryngology · 2026Guideline
- Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis.Sleep medicine · 2024Pooled it
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea.European respiratory review : an official journal of the European Respiratory Society · 2021Guideline
- Long-term effects of weight-reducing drugs in people with hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Effects of a palaeolithic diet on obstructive sleep apnoea occurring in females who are overweight after menopause-a randomised controlled trial.International journal of obesity (2005) · 2022Trial
- The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.Diabetes care · 2020Trial
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.International journal of obesity (2005) · 2016 · on this mapTrial
- Efficacy of uvulopalatopharyngoplasty combined with oral appliance in treatment of obstructive sleep apnea-hypopnea syndrome.Irish journal of medical science · 2015Trial
- A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.Obesity pillars · 2026Article
- Pharmacotherapy in obstructive sleep apnoea: a clinical guide.Sleep & breathing = Schlaf & Atmung · 2026Review
- Current Updates on Pharmacotherapy for Obstructive Sleep Apnea.Journal of rhinology : official journal of the Korean Rhinologic Society · 2026Review
- Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea.Chronic diseases and translational medicine · 2026Review
- Article
- Advances in Non-CPAP Management of Obstructive Sleep Apnea: Spotlight on Pharmacological Therapies.Journal of personalized medicine · 2026Review
- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity.BMJ open diabetes research & care · 2026Review
- Obesity and obstructive sleep apnea: from pathophysiology to current clinical approaches.Respiratory research & clinical practice · 2026Review
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Journal of endocrinological investigation · 2025Review
- 2024 Clinical Practice Guidelines for the Diagnosis and Pharmacologic Treatment of Overweight and Obesity by the Korean Society for the Study of Obesity.Journal of obesity & metabolic syndrome · 2025Review
- Effect of Glucagon-Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea.Obesity science & practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesTo evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA) in obese adults.
designThis phase 2, randomized, double-blind, placebo-controlled study included 2-week screening and 28-week treatment periods. Overnight polysomnography was performed at baseline, Week 8, and Week 28.
settingSingle-center study conducted from August 2008 to September 2009.
participantsForty-five subjects with moderate to severe OSA not receiving positive airway pressure (PAP) treatment with body mass index of 30-40 kg/m(2).
interventionsSubjects were randomized to receive placebo (n = 23) or phentermine 15 mg plus extended-release topiramate 92 mg (n = 22). Both groups received lifestyle-modification counseling. MEASUREMENTS AND
resultsPrimary endpoint, change in apnea-hypopnea index (AHI), significantly favored phentermine 15 mg plus extended-release topiramate 92 mg (-31.5 events/h, 95% CI: -40.0, -22.9) over placebo (-16.6 events/h, 95% CI: -25.0, -8.2) at Week 28 (P =0.0084). At Week 28, there was a 10.2% (95% CI: -12.7, -7.6; 10.8 kg, 95% CI: -13.5, -8.0) mean decrease in weight in the phentermine 15 mg plus extended-release topiramate 92 mg group compared with 4.3% (95% CI: -6.6, -2.0; 4.7 kg, 95% CI: -7.2, -2.2) in the placebo group (P = 0.0006) and a positive, significant (P = 0.0003) correlation between percent change in weight and change in AHI. Significant improvements in overnight oxygen saturation and reduction in blood pressure compared with placebo were observed. Phentermine 15 mg plus extended-release topiramate 92 mg was well tolerated with low adverse event rates.
conclusionsPhentermine 15 mg plus extended-release topiramate 92 mg induced significant weight reductions and concomitant improvements in OSA and related symptoms vs placebo. This suggests weight loss mediated by phentermine 15 mg plus extended-release topiramate 92 mg may be useful in treatment of moderate to severe OSA in obese subjects unable or unwilling to comply with PAP treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.